CD19 and acute lymphoblastic leukemia: These studies have reported high response rates and pioneered the approval of the first anti-CD19 CAR T-cell therapy, tisagenlecleucel, a second generation 4-1BB based CAR for relapsed/refractory (r/r) ALL in children and young adults [7].